Empagliflozin benefits in patients with heart failure and preserved ejection fraction

被引：0
|
作者：
机构：
来源：
Nature Medicine | 2022年 / 28卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Subgroup analysis of the EMPEROR-Preserved clinical trial of the glucose-lowering drug empagliflozin in chronic heart failure with left ventricular ejection fraction (LVEF) >40% found improved clinical outcomes in the cohort of patients with LVEF ≥50%. This is, to our knowledge, the first time a drug therapy has been unequivocally demonstrated to benefit this patient population.
引用
收藏
页码：2480 / 2481
页数：1
相关论文
共 50 条
  • [21] Empagliflozin for Heart Failure With Preserved Left Ventricular Ejection Fraction With and Without Diabetes
    Filippatos, Gerasimos
    Butler, Javed
    Farmakis, Dimitrios
    Zannad, Faiez
    Ofstad, Anne Pernille
    Ferreira, Joao Pedro
    Green, Jennifer B.
    Rosenstock, Julio
    Schnaidt, Sven
    Brueckmann, Martina
    Pocock, Stuart J.
    Packer, Milton
    Anker, Stefan D.
    CIRCULATION, 2022, 146 (09) : 676 - 686
  • [22] Management of heart failure with preserved ejection fraction: from neurohormonal antagonists to empagliflozin
    Alberto Aimo
    Michele Senni
    Andrea Barison
    Giorgia Panichella
    Claudio Passino
    Antoni Bayes-Genis
    Michele Emdin
    Heart Failure Reviews, 2023, 28 : 179 - 191
  • [23] Management of heart failure with preserved ejection fraction: from neurohormonal antagonists to empagliflozin
    Aimo, Alberto
    Senni, Michele
    Barison, Andrea
    Panichella, Giorgia
    Passino, Claudio
    Bayes-Genis, Antoni
    Emdin, Michele
    HEART FAILURE REVIEWS, 2023, 28 (01) : 179 - 191
  • [24] Empagliflozin in heart failure with preserved ejection fraction: first success in mission impossible
    Sciatti, Edoardo
    Gori, Mauro
    D'elia, Emilia
    Iacovoni, Attilio
    Senni, Michele
    EUROPEAN HEART JOURNAL SUPPLEMENTS, 2022, 24 : I153 - I159
  • [25] Anaemia, erythrocytosis, and empagliflozin in heart failure with preserved ejection fraction: the EMPEROR-Preserved trial
    Ferreira, Joao Pedro
    Zannad, Faiez
    Vasques-Novoa, Francisco
    Neves, Joao Sergio
    Filippatos, Gerasimos
    Pocock, Stuart J.
    Butler, Javed
    Packer, Milton
    Anker, Stefan D.
    EUROPEAN HEART JOURNAL, 2024,
  • [26] Empagliflozin in resistant hypertension and heart failure with preserved ejection fraction: the EMPEROR-Preserved trial
    Boehm, Michael
    Butler, Javed
    Coats, Andrew
    Lauder, Lucas
    Mahfoud, Felix
    Filippatos, Gerasimos
    Ferreira, Joao Pedro
    Pocock, Stuart J.
    Brueckmann, Martina
    Hauske, Sibylle J.
    Schueler, Elke
    Wanner, Christoph
    Verma, Subodh
    Zannad, Faiez
    Packer, Milton
    Anker, Stefan D.
    EMPEROR Preserved Trial Committees Investigators
    EUROPEAN HEART JOURNAL, 2025, 46 (14) : 1304 - 1317
  • [27] Association of heart rate with heart failure outcomes and the effects of empagliflozin in patients with preserved ejection fraction - EMPEROR-Preserved trial
    Boehm, M.
    Anker, S. D.
    Mahfoud, F.
    Filippatos, G.
    Ferreira, J. P.
    Pocock, S. J.
    Brueckmann, M.
    Linetzky, B.
    Schueler, E.
    Wanner, C.
    Zannad, F.
    Packer, M.
    Butler, J.
    EUROPEAN HEART JOURNAL, 2022, 43 : 983 - 983
  • [28] Catheter ablation of atrial fibrillation benefits the patients with heart failure and preserved ejection fraction as well as those with heart failure and reduced ejection fraction
    Yamauchi, R.
    Morishima, I
    Morita, Y.
    Takagi, K.
    Nagai, H.
    Kanzaki, Y.
    Watanabe, N.
    Komeyama, S.
    Sugiyama, H.
    Shimojo, K.
    Imaoka, T.
    Sakamoto, G.
    EUROPEAN HEART JOURNAL, 2020, 41 : 430 - 430
  • [29] HEART FAILURE IN PATIENTS WITH PRESERVED EJECTION FRACTION - PUMPING HEART FAILURE?
    Sokolov, A. A.
    Martsinkevich, G., I
    KARDIOLOGIYA, 2018, 58 (06) : 79 - 84
  • [30] The Benefits of Exercise Training on Aerobic Capacity in Patients with Heart Failure and Preserved Ejection Fraction
    Leite do Prado, Danilo Marcelo
    Rocco, Eneas Antonio
    EXERCISE FOR CARDIOVASCULAR DISEASE PREVENTION AND TREATMENT: FROM MOLECULAR TO CLINICAL, PT 2, 2017, 1000 : 51 - 64
12345